Adherence in tamoxifen therapy after conversion to a rebate pharmaceutical in breast cancer patients in Germany

International Journal of Clinical Pharmacology and Therapeutics

Volumn 51, Issue 12, 2013, Pages 969-975

  Kostev, Karel ^a   May, Uwe ^b   Hog, Daniela ^b   Eisel, Janine ^b   Kremmers, Tim ^b   Kosteic, Marjan ^b   Waehlert, Lilia ^b   Hadji, Peyman ^c  

^a IQVIA   (United States)

^b FRESENIUS UNIVERSITY OF APPLIED SCIENCES   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Adherence; Adjuvant therapy; Breast cancer; Compliance; Database; Discount contract; Persistence; Rebate contract

Indexed keywords

TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; COMORBIDITY; COST CONTROL; DEPRESSION; DIABETES MELLITUS; DRUG COST; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; GERMANY; GYNECOLOGIST; HUMAN; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; OSTEOPOROSIS; PATIENT COMPLIANCE; THROMBOSIS; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; GERMANY; HEALTH CARE COSTS; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; TAMOXIFEN;

EID: 84891289822     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201969     Document Type: Article

References (29)

1. http://www.pharmazeutische-zeitung.de/index.php?id=3821.
2. Institut für Demoskopie Allensbach. Gesundheitsund Arzneimittelversorgung in der deutschen Bevölkerung, Eine Repräsentativbefragung der Bevölkerung ab 16 Jahre, Umfrage 10042, Allensbach 2009.
3. Deutsche Pharmazeutische Gesellschaft V. Gute Substitutionspraxis" GSP Leitlinie. http://www.dphg.de/lib/dphg-leitlinie01-gsp-02-1.pdf.
4. Gröber-Grätz D, Gulich M. [Drug therapy in primary care in the light of discount contracts to health insurers - a patient survey]. Z Evid Fortbild Qual Gesundhwes. 2010; 104: 99-105. PubMed
5. Düsing R. Therapietreue bei medikamentöser Behandlung. Dtsch Med Wochenschr. 2006; 131 (46 Spec No): H28-H30. CrossRef PubMed
6. Hadji P. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol. 2010; 73: 156-166. CrossRef PubMed
7. Hadji P, Ziller V, Kyvernitakis J, Bauer M, Haas G, Schmidt N, Kostev K. Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis. Breast Cancer Res Treat. 2013; 138: 185-191. CrossRef [Epub ahead of print]. PubMed
8. Ogdie A, Langan S, Parkinson J, Dattani H, Kostev K, Gelfand JM. Medical Record Databases. In: Strom BL, Kimmel S, Hennessy S (eds). Pharmacoepidemiology. 5th ed. Philadelphia, PA; University of Pennsylvania; 2012. p. 224-243.
9. Kostev K, Haas G (eds). Medical Care in Germany. Epidemiology, Health Economics and Outcome Research with IMS Patient Databases. Göttingen: Optimus; 2011. p. 3-7.
10. Becher H, Kostev K, Schröder-Bernhardi D. Validity and representativeness of the "Disease Analyzer" patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther. 2009; 47: 617-626. PubMed
11. Motheral B, Brooks J, Clark MA, Crown WH, Davey P, Hutchins D, Martin BC, Stang P. A checklist for retrospective database studies - report of the ISPOR Task Force on Retrospective Databases. Value Health. 2003; 6: 90-97. Cross-Ref PubMed
12. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010; 46: 765-781. Cross-Ref PubMed
13. Robert Koch Institut. Krebs in Deutschland (accessed August 20, 2012.) http://www.krebsdaten. de/Krebs/DE/Home/Datenbankabfrage/datensaetze-gesamt- tabelle.html.
14. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365: 1687-1717. CrossRef PubMed
15. Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD; International Breast Cancer Study Group. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol. 2006; 24: 1332-1341. CrossRef PubMed
16. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008; 26: 556-562. CrossRef PubMed
17. Sedjo RL, Devine S. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat. 2011; 125: 191-200. CrossRef PubMed
18. Partridge AH, Wang PS, Winer EP, Avorn J. Non-adherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003; 21: 602-606. CrossRef PubMed
19. Huiart L, Bouhnik AD, Rey D, Tarpin C, Cluze C, Bendiane MK, Viens P, Giorgi R. Early discontinuation of tamoxifen intake in younger women with breast cancer: is it time to rethink the way it is prescribed? Eur J Cancer. 2012; 48: 1939-1946. CrossRef PubMed
20. Wigertz A, Ahlgren J, Holmqvist M, Fornander T, Adolfsson J, Lindman H, Bergkvist L, Lambe M. Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study. Breast Cancer Res Treat. 2012; 133: 367-373. CrossRef PubMed
21. Nekhlyudov L, Li L, Ross-Degnan D, Wagner AK. Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. Breast Cancer Res Treat. 2011; 130: 681-689. CrossRef PubMed
22. Danilak M, Chambers CR. Adherence to adjuvant endocrine therapy in women with breast cancer. J Oncol Pharm Pract. 2013; 19: 105-110. PubMed
23. Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012; 134: 459-478. CrossRef. Published online June 12, 2012. PubMed
24. Korupp A. Medical problems and risks with the discount contract law changeover of inhalers in Germany. Dtsch Med Wochenschr. 2008; 133: 1857. author reply 1857-1858.
25. Gröber-Grätz D, Gulich M. [Drug therapy in primary care in the light of discount contracts to health insurers - a patient survey]. Z Evid Fortbild Qual Gesundhwes. 2010; 104: 99-105. PubMed
26. Leutgeb R, Mahler C, Laux G, Weschnetz A, Szecsenyi J. [Health insurance discount contracts: problems and risks for the general practitioner in the medical care of patients with chronic illness]. Dtsch Med Wochenschr. 2009; 134: 181-186. CrossRef PubMed
27. Schmidt K. [More and more discount contracts. A chance to be free of the budget pressure]. MMW Fortschr Med. 2007; 149: 54-55. PubMed
28. Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. J Antimicrob Chemother. 2002; 49: 897-903. CrossRef PubMed
29. Gräf M. Die volkswirtschaftlichen Kosten der Non-Compliance; Schriften zur Gesundheitsökonomie Bd. 56, Bayreuth 2007.